AmoyDx has a market-leading portfolio of molecular tests and is the therapy diagnostics partner for several major multinational pharmaceutical companies offering precision therapies for cancer. It is the largest provider of molecular diagnostics products for personalized healthcare inР’В China, as well as a service center for oncology biomarker analysis.

Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.Р”Р„moy Diagnostics Co., Ltd.Р’В (SZSE: 300685)Р’В is a leading biotech company which pioneered the development and commercialization of cancer diagnostics inР’В China. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.

This alliance is committed to product development for HRD testing, education and to provide high-quality HRD molecular testing services throughout the diagnosis and treatment of ovarian cancer patients, aiming to ensure maximum benefit for the patients.Р”Р„straZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. An HRD test is a type of genomic test that examines your tumorРІР‚в„ўs DNA to find changes that affect various cancer behaviors. A biomarker is a characteristic of cancer that can be used to inform the way your tumor progresses and may help to identify possible treatment options. The alliance consists of Chinese ovarian cancer experts and leading companies in this field. HRD is an important biomarker of advanced ovarian cancer. On January 30, 2021, the China HRD Testing Alliance Founding Conference was successfully held in Shanghai.

The agreement further expands the cooperation between two companies and will allow more ovarian cancer patients to benefit from targeted therapies. This is another milestone of the two companiesРІР‚в„ў cooperation in the field of precision medicine after the AmoyDxР’В®Р’В BRCA1Р’В /Р’В BRCA2Р’В Kit was successfully approved as CDx for Olaparib about two years ago. The agreement was signed during the China HRD Testing Alliance Founding Conference with the aim to join efforts of HRD CDx kit development and its post-launch marketing in ovarian cancer. Xiamen, China, 19th February, 2021 РІР‚вЂњР’В Recently Amoy Diagnostics Co., Ltd.Р’В (AmoyDx, SZSE: 300685) announced that it signed an agreement with AstraZeneca to develop a Homologous Recombination Deficiency (HRD) Companion Diagnostic (CDx) in ovarian cancer.

Hrd cancer